117 related articles for article (PubMed ID: 26485746)
1. Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Yao DM; Ma JC; Wen XM; Guo H; Lin J; Qian J
Clin Chem Lab Med; 2016 May; 54(5):865-71. PubMed ID: 26485746
[TBL] [Abstract][Full Text] [Related]
2. DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.
Zhou JD; Zhang TJ; Wang YX; Yang DQ; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Tumour Biol; 2016 Jul; 37(7):8951-60. PubMed ID: 26753961
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia.
Zhou JD; Wang YX; Zhang TJ; Yang DQ; Yao DM; Guo H; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Biochem Biophys Res Commun; 2015 Aug; 463(4):1250-6. PubMed ID: 26086097
[TBL] [Abstract][Full Text] [Related]
4. Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Ohdan H; Okada M
Ann Thorac Surg; 2015 May; 99(5):1746-54. PubMed ID: 25825198
[TBL] [Abstract][Full Text] [Related]
5. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome.
Qian J; Chen XX; Qian W; Yang J; Wen XM; Ma JC; Deng ZQ; Qian Z; Zhang YY; Lin J
Clin Chem Lab Med; 2014 Dec; 52(12):1859-65. PubMed ID: 25153418
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P
Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome.
Kang H; Wang X; Gao L; Cen J; Li M; Wang W; Wang N; Li Y; Wang L; Yu L
Eur J Med Res; 2015 Feb; 20(1):16. PubMed ID: 25889027
[TBL] [Abstract][Full Text] [Related]
8. Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome.
Zhang YY; Zhou JD; Yang DQ; He PF; Yao DM; Qian Z; Yang J; Xu WR; Lin J; Qian J
Clin Chem Lab Med; 2018 Feb; 56(3):485-491. PubMed ID: 29031013
[TBL] [Abstract][Full Text] [Related]
9. CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression.
Zhao X; Yang F; Li S; Liu M; Ying S; Jia X; Wang X
Br J Haematol; 2014 Jun; 165(5):649-58. PubMed ID: 24601943
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of aberrant SOCS-1 gene promoter methylation in myelodysplastic syndromes patients.
Chaubey R; Sazawal S; Mahapatra M; Chhikara S; Saxena R
Int J Lab Hematol; 2015 Apr; 37(2):265-71. PubMed ID: 25123164
[TBL] [Abstract][Full Text] [Related]
11. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
[TBL] [Abstract][Full Text] [Related]
12. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
Grövdal M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Wallvik J; Tangen JM; Oberg G; Jacobsen SE; Hokland P; Porwit A; Hellström-Lindberg E
Clin Cancer Res; 2007 Dec; 13(23):7107-12. PubMed ID: 18056190
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
14. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX
Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
[TBL] [Abstract][Full Text] [Related]
15. [Whole genome methylation profiles of myelodysplastic syndrome and its diagnostic value].
Zhao X; Wang X; Li S; Li N; Ma Y; Lin G
Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):944-8. PubMed ID: 25339336
[TBL] [Abstract][Full Text] [Related]
16. Abnormal methylation of the sex-determining region Y-box 17 (SOX17) promoter predicts poor prognosis in myelodysplastic syndrome.
Fan R; Zhao XL; Wang H; He HY; Peng ZP; Yang B; Han T; Wang W; Wang XQ; Lin GW
Clin Lab; 2014; 60(9):1465-74. PubMed ID: 25291942
[TBL] [Abstract][Full Text] [Related]
17. Aberrant DNA methylation of DLX4 and SIM1 is a predictive marker for disease progression of uterine cervical low-grade squamous intraepithelial lesion.
Sakane J; Taniyama K; Miyamoto K; Saito A; Kuraoka K; Nishimura T; Sentani K; Oue N; Yasui W
Diagn Cytopathol; 2015 Jun; 43(6):462-70. PubMed ID: 25614457
[TBL] [Abstract][Full Text] [Related]
18. CXXC4 mRNA levels are associated with clinicopathological parameters and survival of myelodysplastic syndrome patients.
Li S; Fan R; Zhao XL; Wang XQ
Leuk Res; 2014 Sep; 38(9):1072-8. PubMed ID: 25085016
[TBL] [Abstract][Full Text] [Related]
19. [Significance of methylation status of zo-1 gene in differential diagnosis for myelodysplastic syndrome].
Kang HY; Wang XR; Wang LL; Wang C; Cen J; Gao L; Liu Y; Li YH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):76-80. PubMed ID: 21362226
[TBL] [Abstract][Full Text] [Related]
20. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome.
Qian J; Yao DM; Lin J; Wang YL; Han LX; Xu WR; Wu CY
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):74-81. PubMed ID: 19196380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
